Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes.

The cysteinyl leukotrienes (CysLTs) are important mediators of human asthma. Pharmacologic and clinical studies show that the CysLTs exert most of their bronchoconstrictive and proinflammatory effects through activation of a putative, 7-transmembrane domain, G-protein-coupled receptor, the CysLT1 receptor. The initial molecular characterization of the CysLT1 receptor showed by in situ hybridization, the presence of CysLT1 receptor messenger RNA (mRNA) in human lung smooth-muscle cells and lung macrophages. We confirmed the results of these in situ hybridization analyses for the CysLT1 receptor, and produced the first immunohistochemical characterization of the CysLT1 receptor protein in human lung. The identification of the CysLT1 receptor in the lung is consistent with the antibronchoconstrictive and antiinflammatory actions of CysLT1 receptor antagonists. We also report the expression of CysLT1 receptor mRNA and protein in most peripheral blood eosinophils and pregranulocytic CD34+ cells, and in subsets of monocytes and B lymphocytes.

[1]  M. David,et al.  Rapid STAT Phosphorylation via the B Cell Receptor , 1999, The Journal of Biological Chemistry.

[2]  J. Chambers,et al.  Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. , 1999, Molecular pharmacology.

[3]  Y. Nasuhara,et al.  Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. , 1999, American journal of respiratory and critical care medicine.

[4]  L. Boulet,et al.  Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. , 1999, The European respiratory journal.

[5]  Jilly F. Evans,et al.  Characterization of the human cysteinyl leukotriene CysLT1 receptor , 1999, Nature.

[6]  R. Welliver,et al.  Increased production of IFN-γ and cysteinyl leukotrienes in virus-induced wheezing , 1999 .

[7]  Lynn Wei,et al.  Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma , 1999, Annals of Internal Medicine.

[8]  A. Zwinderman,et al.  The effect of montelukast (MK‐0476), a cysteinyl leukotriene receptor antagonist, on allergen‐induced airway responses and sputum cell counts in asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  K. McDowell.  Montelukast, A Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction , 1999 .

[10]  S. Dahlén,et al.  Exposure of healthy volunteers to swine house dust increases formation of leukotrienes, prostaglandin D2, and bronchial responsiveness to methacholine , 1998, Thorax.

[11]  L Hendeles,et al.  Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. , 1998, The New England journal of medicine.

[12]  R. Dockhorn,et al.  Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. , 1998, Archives of internal medicine.

[13]  W. Busse.  Leukotrienes and inflammation. , 1998, American journal of respiratory and critical care medicine.

[14]  J. Bernstein,et al.  Montelukast for Chronic Asthma in 6- to 14-Year-Old Children A Randomized, Double-blind Trial , 1998 .

[15]  Takao Shimizu,et al.  Leukotriene D4 Activates Mitogen-activated Protein Kinase through a Protein Kinase Cα-Raf-1-dependent Pathway in Human Monocytic Leukemia THP-1 Cells* , 1998, The Journal of Biological Chemistry.

[16]  T. Reiss,et al.  Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. , 1997, Thorax.

[17]  A. Leff,et al.  Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. , 1997, American journal of respiratory and critical care medicine.

[18]  P. Sterk,et al.  The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. , 1997, American journal of respiratory and critical care medicine.

[19]  S. Suissa,et al.  Effectiveness of the Leukotriene Receptor Antagonist Zafirlukast for Mild-to-Moderate Asthma , 1997, Annals of Internal Medicine.

[20]  K. Austen,et al.  Molecular cloning of the gene for human leukotriene C4 synthase. Organization, nucleotide sequence, and chromosomal localization to 5q35. , 1996, The Journal of biological chemistry.

[21]  J. Demartino,et al.  Cloning, expression, and characterization of the human eosinophil eotaxin receptor , 1996, The Journal of experimental medicine.

[22]  C. P. Green,et al.  Persistent increase in plasma and urinary leukotrienes after acute asthma. , 1995, Archives of disease in childhood.

[23]  D. Woodward,et al.  Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro , 1994, Journal of leukocyte biology.

[24]  T. Haahtela,et al.  Leukotriene E4 and granulocytic infiltration into asthmatic airways , 1993, The Lancet.

[25]  C. Labat,et al.  A second cysteinyl leukotriene receptor in human lung. , 1992, The Journal of pharmacology and experimental therapeutics.

[26]  D. Steinhilber,et al.  On the expression and regulation of 5-lipoxygenase in human lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Robert A. Lewis,et al.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.

[28]  U. Francke,et al.  CD14 is a member of the family of leucine-rich proteins and is encoded by a gene syntenic with multiple receptor genes. , 1990, Journal of immunology.

[29]  A. Jesaitis,et al.  Regulation of chemoattractant receptor interaction with transducing proteins by organizational control in the plasma membrane of human neutrophils , 1989, The Journal of cell biology.

[30]  B. Samuelsson.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. , 1983, Science.

[31]  T. Zuberbier,et al.  Mast cell and myeloid marker expression during early in vitro mast cell differentiation from human peripheral blood mononuclear cells. , 2000, The Journal of investigative dermatology.

[32]  R. Welliver,et al.  Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. , 1999, The Journal of allergy and clinical immunology.

[33]  A. Kay,et al.  CD34(+)/interleukin-5Ralpha messenger RNA+ cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors. , 1999, American journal of respiratory cell and molecular biology.

[34]  W. Busse,et al.  Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. , 1997, The Journal of asthma : official journal of the Association for the Care of Asthma.

[35]  K. Metters.  Leukotriene receptors. , 1995, Journal of lipid mediators and cell signalling.

[36]  J. Drazen,et al.  Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.